NDA 021489 · Bracco
Prohance Multipack
Gadoteridol · Injection · Paramagnetic Contrast Agent
Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Oct 9, 2003
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
4 Phase 3, 2 recruiting
FAERS reports
1,816
1,516 serious, 162 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. ProHance is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of ProHance in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: chronic, severe kidney disease (GFR less than 30 mL/min/1.73m 2 ), or acute...
What it is approved for
From the label in effect Mar 14, 2025.
ProHance Multipack is a gadolinium-based contrast agent indicated for magnetic resonance imaging (MRI) to visualize: lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues in adults and pediatric patients, including term neonates ( 1.1 ) lesions in the head and neck in adults ( 1.2 ) 1.1 MRI of the Central Nervous System (CNS) ProHance is indicated for magnetic resonance imaging (MRI) in adults and pediatric patients including term neonates to visualize lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. 1.2 MRI of Extracranial/Extraspinal Tissues ProHance is indicated for MRI in adults to visualize lesions in the head and neck.
Mechanism: Gadoteridol is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment produced by the paramagnetic agent results in a relatively large local magnetic field, which can enhance the relaxation rates of water protons in the vicinity of the paramagnetic agent. In MRI, visualization of normal and pathologic brain tissue depends, in part, on variations in the radiofrequency signal intensity that occur with: 1) differences in proton density; 2) differences of the spin-lattice or longitudinal relaxation times (T1); and 3)...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2020 Supplement 14 · Efficacy LetterLabel
- Oct 9, 2003 Original approval · Type 3 - New Dosage Form Other Important Information from FDALetterReview
1 products under this application
- PROHANCE MULTIPACK · GADOTERIDOL 279.3MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadoteridol" as an intervention, any sponsor and status, largest first.
GuerbetIndustry
NCT04373564 · 2,076 participants (planned) · Start Mar 24, 2021 · Primary completion Dec 31, 2028
Drug: Gadoxetate disodium; Gadobenate dimeglumine and 4 more · For: Motor Function; Cognitive Function; Contrast Media
Sites: Scottsdale, Arizona; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05915728 · 410 participants · Start Jul 24, 2023 · Primary completion May 31, 2024
Drug: Gadoquatrane (BAY1747846); Gadobutrol and 2 more · For: Contrast Enhancement in Magnetic Resonance Imaging; Non-central Nervous System Pathology
Sites: Birmingham, Alabama; Indian Wells, California; Orange, California · 85 sites in all
- Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) ImagingPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00709852 · 402 participants · Start Jun 2008 · Primary completion Apr 2009
Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Gadoteridol (ProHance) · For: Diagnostic Imaging; Central Nervous System Diseases
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Los Gatos, California · 79 sites in all
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related ProblemsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05915702 · 321 participants · Start Jul 24, 2023 · Primary completion May 30, 2024
Drug: Gadoquatrane (BAY1747846); Gadobutrol and 2 more · For: Contrast Enhancement in Magnetic Resonance Imaging; Central Nervous System Pathology
Sites: Indian Wells, California; Orange, California; Miami, Florida · 78 sites in all
- Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the BrainPivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT01613417 · 229 participants · Start Aug 2012 · Primary completion Apr 2014
Drug: gadoteridol; gadobutrol · For: Brain Disease
Sites: Teaneck, New Jersey
- SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00522951 · 165 participants · Start Aug 2007 · Primary completion Aug 2008
Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Gadobutrol (Gadavist, Gadovist, BAY86-4875) and 1 more · For: Brain Metastases
Sites: Nagoya, Japan; Matsuyama, Japan; Kitakyushu, Japan · 20 sites in all
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT04879628 · 129 participants · Start Jun 7, 2021 · Primary completion Sep 21, 2022
Drug: SAR441344 IV; placebo IV and 3 more · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Tampa, Florida; Charlotte, North Carolina · 37 sites in all
- Baseline Cortical Haemodynamics in MSStatus unknown
University of NottinghamAcademic, hospital or other
NCT02481882 · 80 participants (planned) · Start Jan 2017 · Primary completion Oct 2019
Drug: Prohance (Gadoteridol) · For: Multiple Sclerosis
Sites: Nottingham, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nephrogenic systemic fibrosis587
- pain407
- anxiety254
- emotional distress223
- mobility decreased186
- general physical health deterioration184
- fibrosis183
- injury178
- scar159
- skin hypertrophy154
- skin induration151
- pruritus147
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 27 |
| 2005 | 28 |
| 2006 | 41 |
| 2007 | 42 |
| 2008 | 47 |
| 2009 | 70 |
| 2010 | 176 |
| 2011 | 208 |
| 2012 | 92 |
| 2013 | 50 |
| 2014 | 121 |
| 2015 | 33 |
| 2016 | 64 |
| 2017 | 78 |
| 2018 | 85 |
| 2019 | 93 |
| 2020 | 85 |
| 2021 | 125 |
| 2022 | 68 |
| 2023 | 63 |
| 2024 | 75 |
| 2025 | 62 |
| 2026 | 83 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Prohance Multipack (Gadoteridol) · HCPCS A9576
2024 spending
$407K
Beneficiaries
17,496
19,261 claims
Per beneficiary
$23
2024 ASP limit $1.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $328,533 |
| 2021 | $373,358 |
| 2022 | $405,189 |
| 2023 | $435,799 |
| 2024 | $407,440 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA, Shankar PR, Gagnier JJ, et al. · JAMA Intern Med 2020 · Meta-Analysis, Systematic Review
- PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma.
Mueller S, Kline C, Stoller S, et al. · Neuro Oncol 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Efficacy evaluation of gadoteridol for MR angiography of intracranial vascular lesions.
McLachlan SJ, Francisco JC, Pernicone JR, et al. · J Magn Reson Imaging 1994 · Clinical Trial, Clinical Trial, Phase III
- Delineation of gliomas with various doses of MR contrast material.
Yuh WT, Nguyen HD, Tali ET, et al. · AJNR Am J Neuroradiol 1994 · Clinical Trial, Clinical Trial, Phase II
- Worldwide clinical safety assessment of gadoteridol injection: an update.
Runge VM, Parker JR · Eur Radiol 1997 · Clinical Trial, Clinical Trial, Phase I
- Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J, Saini S, Mitchell DG, et al. · AJR Am J Roentgenol 1995 · Clinical Trial, Clinical Trial, Phase III
Sponsor: Bracco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.